Loading
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Regular session
$1.73
+$0.05 · +2.98%
Regular session · ET · Market data may be delayed.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Day range
Current $1.73
52-week range
Current $1.73
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
41
Fair Value
Sentiment
58
Mixed
Risk
66
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Day range
Current $1.73
52-week range
Current $1.73
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 6.82M USD | 3.77M USD | 3.23M USD | 242K USD | 249K USD |
| Selling, general, and administrative | 5.16M USD | 4.47M USD | 8.16M USD | 2M USD | 813K USD |
| Operating expenses | 11.98M USD | 8.24M USD | 11.39M USD | 2.24M USD | 1.06M USD |
| Interest income | 21K USD | 25K USD | — | — | — |
| Interest expense | — | — | 2.08M USD | 653K USD | 547K USD |
| Depreciation and amortization | 4K USD | 4K USD | 4K USD | 3K USD | 73K USD |
| Operating income | −11.98M USD | −8.24M USD | −11.39M USD | −2.24M USD | −1.06M USD |
| Net income | −11.96M USD | −8.21M USD | −13.04M USD | −3.22M USD | −1.56M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Dow Jones Global Real Estate ETFRWO1.03M0.09%1.18B USD0.50%$46.26+0.48%
State Street SPDR Dow Jones International Real Estate ETFRWX807.69K0.34%240.55M USD0.59%$25.135+0.50%
State Street SPDR S&P International Small Cap ETFGWX331.84K0.04%917.55M USD0.40%$45.50+0.80%
State Street SPDR Portfolio Europe ETFSPEU59.7K0.01%687.66M USD0.07%$53.07+0.57%
Vanguard Extended Market ETFVXF41.03K0.00%95.4B USD0.05%$235.13+0.86%State Street SPDR Dow Jones Global Real Estate ETFRWOState Street SPDR Dow Jones International Real Estate ETFRWXState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
